Surgical and chemotherapeutic experience regarding a urachal carcinoma with repeated relapse: case report and literature review by Liang Zong & Ping Chen
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Zong and Chen World Journal of Surgical Oncology 2013, 11:170
http://www.wjso.com/content/11/1/170CASE REPORT Open AccessSurgical and chemotherapeutic experience
regarding a urachal carcinoma with repeated
relapse: case report and literature review
Liang Zong and Ping Chen*Abstract
Background: Urachal carcinoma is a rare tumor that is usually associated with a poor prognosis, especially the
pathological type, urachal mucinous adenocarcinoma. Surgery remains the primary treatment in prolonging the
overall survival time of patients.
Case presentation: We report on a 41-year-old woman with urachal mucinous adenocarcinoma who underwent
three surgeries and several courses of chemotherapy over a 42-month period. The first surgery, involving en-bloc
excision of the urachal mass, partial urinary bladder, urachal ligament, and umbilicus was performed in May 2007. It
is well known that the correct surgical scheme plays a key role in preventing recurrence or metastasis. However, a
second debulking surgery with only a single salpingo-oophorectomy may have contributed directly to the patient’s
subsequent left ovarian metastasis. Therefore, we strongly recommend performing a bilateral salpingo-
oophorectomy once ovarian metastasis has been detected, even if the metastasis is only present on one side.
Although postoperative adjuvant chemotherapy regimens, first with Taxol, carboplatin, gemcitabine, and cisplatin,
and then with IFO, EPI, and mesna were consecutively administered after the first and second surgeries, they
seemed less effective, since recurrence and metastasis occurred shortly after each surgical treatment. After a third
debulking surgery in June 2009, docetaxel, oxaliplatin, and capecitabine were administered. This chemotherapy
regimen was chosen based on an immunohistochemical test that involved the multidrug resistance gene; this test
indicated that the urachal mucinous adenocarcinoma was resistant to the two chemotherapy regimens used
previously. Surprisingly, the patient exhibited a marker response to the new regimen and the metastatic foci
entered into a stable disease stage. However, the patient still died of diffuse metastatic disease 1.5 years later.
During the whole period of treatment, we found that serum tumor markers including CA724, CA125, CA19-9, and
CEA were elevated in a linear pattern, with parallel increases in line with peritoneal carcinomatosis and parallel
reductions in line with response to personalized chemotherapy.
Conclusion: Personalized treatment can be given to those patients who experience a poor response to initial
therapy. Moreover, an immunohistochemical test for the multidrug resistance gene and serum tumor markers may
supply key information in the choice of reasonable chemotherapeutics.
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Figure 1 Pathological section with hematoxylin and eosin
staining after surgery. (A) First surgery. (B) Second surgery.
(C) Third surgery.
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Urachal carcinoma is a rare form of tumor that usually
originates in the bladder, and represents 0.01% of all
cancers. Moreover, this lesion accounts for 0.34-0.7%
of all bladder carcinomas [1]. Pathologically, a recent
population-based analysis has revealed that adenocar-
cinoma is very common among urachal carcinomas and
represents approximately 10% of all bladder adenocar-
cinomas [2]. The most common histological type of
urachal adenocarcinoma is mucinous adenocarcinoma
[3]. However, the rare variant form known as signet-
ring cell carcinoma accounts for only a small proportion
of the urachal mucinous adenocarcinomas. Until now,
urachal adenocarcinoma has been regarded as associ-
ated with poor prognosis, especially in the case of
urachal mucinous adenocarcinoma [4,5]. Surgery re-
mains the primary treatment for prolonging the overall
survival time of patients. However, the appropriate
initial surgical treatment is a matter of controversy. No
standard chemotherapy regimens for advanced urachal
carcinoma have yet been established.
Case presentation
In June 2007, a 41-year-old woman was referred to our
hospital with a palpable mass in her lower abdomen.
Computed tomography showed a large mass located in
the anterior pelvic cavity just superior to the bladder,
but no other positive findings elsewhere. Because of the
limited clinical evidence for diagnosis, laparotomy was
performed for this patient. Laparotomy revealed a
12.0 × 12.0 × 9.0 cm solid lesion, which extended from
the vertex of the bladder to the umbilicus. The lesion
was removed en bloc together with the umbilicus, bladder
dome, and adjacent peritoneum. Pathological diagnosis
confirmed it to be a urachal mucinous adenocarcinoma
(Figure 1A). At 1 month after diagnosis, this patient
received adjuvant chemotherapy consisting of four cycles
of Taxol and carboplatin. However, this regimen seemed
ineffective in preventing disease progression because mul-
tiple hepatic metastases were found at only 6 months after
surgery (Figure 2A). Accordingly, a revised chemothera-
peutic strategy with four cycles of gemcitabine and cis-
platin, as well as one cycle of interventional therapy, was
administered sequentially. However, a symptom involving
lower abdominal compression was gradually felt over a
1-year period. Because of this, the patient was again ad-
mitted to our hospital. Physical examination showed a
large abdominal mass lying between the xiphoid process
of the sternum and the umbilicus, without obvious ten-
derness. Abdominal computed tomography with periph-
eral enhancement using contrast material in the delayed
phase revealed extrinsic multi-organ compression be-
cause of a giant mass, 27.0 × 17.0 cm, in the abdominal
cavity (Figure 2B). At laparotomy, a giant tumor wasdiscovered adhering to the right ovary, as well as multiple
metastases in the greater omentum and liver (Figure 3).
Moreover, about 300 ml of mucus was found in the pel-
vic cavity, suggesting seeded metastasis. We removed
the tumor en bloc and resected the right ovary and
greater omentum. In addition, we performed a complete
Figure 2 Computed tomography. (A) Multiple hepatic metastases.
(B) giant local recurrent tumor infiltrating right ovary.
Figure 3 27.0 × 17.0 cm giant recurrent tumor. (A) A giant tumor cover
(C) A giant tumor adhering to the right ovary. (D) A giant tumor after rese
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end of the surgery, we implanted a sustained-release
preparation of 5-fluorouracail into the surroundings of the
recurrent tumor, hepatic surface and other suspected
metastatic sites in the abdominal cavity. Pathological ana-
lysis confirmed the tumor to be a recurrent carcinoma
since it was located in the original tumor site (Figure 1B).
Systemic chemotherapy, consisting of four cycles of IFO,
mesna, and EPI, was given as a persistent treatment at
1 month after the second surgery. However, 1.5 years later,
this patient was referred to our department for the third
time with distension of the lower abdomen. Ultrasound
detected a new mass lying in the pelvic cavity. Physical
examination revealed a large abdominal mass of about
10 × 10 cm located in the lower abdomen. During laparot-
omy, a metastatic mass measuring 2 cm in diameter was
excised. When the abdominal cavity was entered, a 10 ×
10 × 8 cm solid mass was found tightly adhering to the left
ovary, as well as multiple hepatic metastases. A debulking
operation was performed to remove the recurrent tumor
and the left ovary. During the third surgery, a sustained-
release preparation of 5-fluorouracail was also implanted
into the recurrent rumor site, the hepatic surface, and
the bottom of the pelvic cavity. Pathological analysis
supported the finding that the lesion was a stable
urachal mucinous adenocarcinoma (Figure 1C). An im-
munohistochemical test involving the multidrug resistance
gene was carried out, in which glutathione s-transferase
was found to be strongly positive. Based on the detection
of multidrug resistance using the gene test, four cycles of
docetaxel, oxaliplatin, and capecitabine were given persist-
ently. After the first cycle, the progression of multi-livered by abundant mucus. (B) A giant tumor lying in abdominal cavity.
ction.
Table 1 Mayo staging system for urachal carcinoma
Stage Definition
I Tumors confined to the urachus and or bladder
II Tumors extending beyond the muscular layer of the urachus or
the bladder
III Tumors infiltrating the regional lymph nodes
IV Tumors infiltrating non-regional lymph nodes or other distant
sites
Zong and Chen World Journal of Surgical Oncology 2013, 11:170 Page 4 of 8
http://www.wjso.com/content/11/1/170-foci stopped, and after the fourth cycle, 20% of these foci
had disappeared. Although the docetaxel, oxaliplatin, and
capecitabine regimen was efficacious in treating the tumor,
temporary myelosuppression was observed, which was off-
set by colony-stimulating factor. However, the patient died
of diffuse metastatic disease at 18 months after individual-
ized treatment.
Conclusion
It is sometimes difficult to differentiate between urachal
and non-urachal carcinomas based only on symptoms.
This is primarily because there is no specific symptom
for urachal carcinoma. Furthermore, most of the tumors
may develop in the submucosa or muscularis, and do
not invade the mucosa of the bladder in the early stage,
so symptoms are not prominent. According to the latest
reports, several different imaging methods may be useful
in aiding diagnosis. Ultrasound can demonstrate a tumor
in the bladder dome associated with a mass containing
calcification [6]. Computed tomography can identify the
extent of the palpable suprapubic mass, localize calcifi-
cation, and determine the involvement of local nodes. In
addition, cystoscopy can reveal a tumor in the bladder
dome, and concurrent bimanual examination can detect a
suprapubic mass. Occasionally, biopsy may be performed
via cystoscopy to confirm a diagnosis before surgery. How-
ever, for a few of the complicated cases or metastatic
cases, a limited number of useful positive findings can
only be made using imaging modalities; under such condi-
tions laparotomy is necessary.
To date, the criteria for making a diagnosis of urachal
carcinoma are not uniform, but clinical findings and
histological evidence are both key factors. The typical
criteria [1,7-9] should include: (a) a tumor in the dome
of the bladder; (b) the presence of urachal residua; (c) an
absence of cystitis cystica and cystitis glandularis; (d) a
sharp demarcation between the tumor and the surface
epithelium of the bladder; (e) the invasion of deeper
muscular tissues with intact or ulcerated epithelium; (f) an
extension of the tumor through the Retzius space; and
(g) no evidence of a primary tumor outside of the
bladder.
Our case was consistent with the typical criteria. How-
ever, for a few uncommon cases, this system is too re-
strictive to fulfill all the prognostic criteria. Two simpler
criteria sets, which are more closely related to clinical
practice, have been suggested by some scientists. The
first set [4] is: (a) a tumor in the dome of the bladder;
(b) the presence of urachal residua; and (c) the absence
of cystitis cystica and cystitis glandularis. The second set
[10] is: (a) a tumor in the dome of the bladder; (b) a
sharp demarcation between the tumor and the surface
epithelium of bladder; and (c) no evidence of a primary
tumor outside of the bladder.Surgical treatment plays a dominant role in the manage-
ment of patients with urachal carcinoma. The achieve-
ment of a complete urachectomy including umbilectomy
and negative surgical margins, and extended partial or
total cystectomy, are crucial to long-term survival [1,11].
The surgical resection margin is one of the most import-
ant iatrogenic factors for prognosis, so resection must be
technically feasible and frozen sections must reveal the
negative resected margins [6]. If only the resection margin
is clear, another important prognostic factor is tumor sta-
ging [11]. Until now, tumors have been staged using two
different staging systems: the Sheldon staging system and
the Mayo staging system. Both systems have predicted
cancer-specific survival equally well, but we recommend
the use of the Mayo staging system in future studies owing
to its simplicity (Table 1). However, both systems need to
be validated in future large trials.
Late presentation of symptoms and fast progression
leading to advanced tumor stage at diagnosis have resulted
in a poor prognosis for urachal carcinoma, which is conse-
quently uniformly fatal. Moreover, urachal adenocarcin-
omas show a tendency to local recurrence and distant
metastasis after surgical treatment, most often (81%) in
the first 2 years [1]. It has been revealed that postoperative
local recurrence takes place earlier than distant metastasis.
The most common sites of local recurrence are the pelvis,
bladder, abdominal wall, and wounds. Distant metastases
have been reported in a number of organs, including the
lung, brain, omentum, liver, bone, and lymph nodes
[1,12-14]. However, ovarian metastasis seems to be rare.
In reviewing the literature, only eight cases with ovarian
metastasis have been previously reported [15-22] (Table 2).
Possible mechanisms of urethral recurrence are thought
to include hematogenous metastasis; dissemination via the
retrograde lymphatic route; and intravesical dissemination.
Current research is focused on the differentiation of pri-
mary and metastatic ovarian tumors. Since the urachal
adenocarcinoma metastasizes to the ovary it may mimic
primary ovarian mucinous carcinoma, and this can lead to
misdiagnosis. Among the eight reported cases [15-22],
three were identified simultaneously with the primary
urachal carcinoma and one was detected as a primary
tumor before urachal adenocarcinoma was confirmed.
Half of the eight cases were histologically identified as
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ings with regard to the metastatic carcinomas were
bilaterality, microscopic surface involvement of epithelial
cells, and an infiltrative pattern of stromal invasion. Less
frequent findings that were exclusive or almost exclusive
to metastatic carcinoma were a nodular invasive pattern,
ovarian hilar involvement, single cell invasion, signet-ring
cells, vascular invasion, and microscopic surface mucin.
However, bilateral presentation of primary ovarian mucin-
ous carcinoma is uncommon. When bilateral ovarian mu-
cinous carcinoma is considered in the diagnosis, it is
essential to exclude the possibility of metastatic carcinoma
completely. The most common primary sites for meta-
static ovarian mucinous carcinoma include the colon,
pancreas, gallbladder, stomach, appendix, and uterine
cervix [23-25]. Bladder adenocarcinoma, including urachal
carcinoma, is a less common candidate for the primary
tumor on these occasions.
Immunohistochemistry is always one important method
for differentiating between primary and metastatic ovarian
mucinous tumors, although there is a considerable overlap
in their immunohistochemical staining patterns. In line
with the latest findings, Lee [22] has recommended
using a panel of CK7, CK20, CDX2, MUC2, 34βE12,Table 2 Summary of key data from eight reported cases of ur
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adenocarcinoma metastasis from primary ovarian mu-
cinous carcinoma, and metastatic carcinoma from other
organs. In Lee’s opinion [22], the coordinated expres-
sion of CK7, CK20, and CDX2 might be helpful in dif-
ferentiating metastatic urachal carcinoma from primary
ovarian mucinous tumor. Firstly, CK20 and CDX-2 are
diffusely and strongly positive in urachal carcinoma,
while about 50% of urachal carcinomas are positive for
CK7, so there are two possible profiles for urachal car-
cinoma (CK7−/CK20+/CDX2+ vs. CK7+/CK20+/CDX2+).
Secondly, CK7 −CK20+ is rarely seen in primary ovarian
mucinous tumor, but CK7+/CK20+ is present in both the
primary ovarian tumor and lower intestinal tract tumors.
Thus, a finding of diffusely and strongly positive CDX2
plays a key role in excluding the primary ovarian tumor.
In addition, because urachal carcinoma is expressed
immunohistochemically as a unique colonic epithelial
epitope that mimics the immunochemical profile of co-
lonic cancer, its presence could be further confirmed by
means of MUC2. Then, the only remaining issue is to dis-
criminate a urachal origin from a lower gastrointestinal
origin. However, 34βE12–/β-catenin + is rarely expressed




































































Figure 4 Immunohistochemical test. (A) Positive staining for
CDX2. (B) Positive staining for MUC2.
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In this case, the immunochemical findings were partly
compatible with the Lee’s diagnostic criteria [22]. CK7 and
CK20 were both negative in our case, but positive
CDX2 and MUC2 confirmed the tumor’s urachal origin
(Figure 4). However, because only a limited number ofTable 3 Summary of response to chemotherapy in reported c
Reference Number of patients Chemotherapy and status at last fo
[18] 1 Paclitaxel and carboplatin
[19] 1 5-flourouracil, cisplatin, and gemcitabin
[20] 1 5-fluorouracil, folinic acid, and oxalipla
[28] 3 5-fluorouracil, doxorubicin, and mitom
[29] 1 5-fluorouracil, mitomycin C, and mitox
[21] Patient 1 5-fluorouracil, doxorubicin, and cisplati
5-fluorouracil, doxorubicin, and etopos
5-fluorouracil, cisplatin, and α interfero
[21] Patient 2 Doxorubicin, cisplatin, and mitomycin
[22] 1 Docetaxel and carboplatin
[30] 1 Tegafur, gimeracil, oteracil, and cisplat
[31] 1 Cisplatin, Adriamycin, vinblastine, andstudies with small sample size have been published on
the immunohistochemical profiles of urachal carcin-
omas, a further large trial is need to provide more reli-
able data.
If suspected metastasis is encountered in the ovary,
whether or not it occurs on one or both sides, it
should be fully investigated and complete resection
should be performed to prolong the patient’s overall
survival time [26,27]. In many conditions, bilateral
salpingo-oophorectomy is essential, since bilateral ovarian
metastasis is the common clinical model. However, with
regard to suspected single metastasis, there is still a debate
on the scope of surgical resection. Kawakami et al. [21]
reported that the use of single salpingo-oophorectomy en-
abled the achievement of a long survival period of more
than 11 years. Conversely, Young [17] performed bilateral
salpingo-oophorectomy, which was followed by early post-
operative multiple metastasis at 7 months. Of course, a
systematic analysis is required to obtain absolute results,
including tumor stage or presence of local recurrence. Al-
though single salpingo-oophorectomy was performed
when metastasis occurred in the right ovary in our case,
we support the use of bilateral salpingo-oophorectomy
even for single metastasis in the ovary, especially for cases
with local recurrence.
Although the role of chemotherapy and radiotherapy
still remain unclear and the effects of other treatments
have not been established, varied chemotherapy regi-
mens have been reported to have some presumptive
advantage [28-31] (Table 3). However, in our case, trad-
itional chemotherapy regimens such as paclitaxel and
carboplatin, 5-fluorouracail, gemcitabine, and cisplatin,
and 5-fluorouracail, IFO, EPI, and mesna seemed less
effective in controlling disease progression. Rapid progres-
sion of disease suggested that our patient’s carcinoma
might have been chemoresistant to these chemotherapeu-
tics. Under such an adverse condition, an individualizedases of urachal carcinoma
llow-up Response Follow-up result
Stable Alive with disease (3 months)
e Complete response Died of disease (38 months)
tin Complete response Died of disease (26 months)
ycin C Partial response Died of disease (12 months)
antrone, Complete response Died of disease (28 months)
n; Complete response Alive without disease (11 years)
ide;
n
C Complete response Alive without disease (10 years)
Complete response Alive with disease (36 months)
in Complete response Alive without disease (30 months)
methotrexate Partial response Alive with disease (13 months)
Figure 5 Tumor markers changing at different follow-up dates.
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mission. Therefore, an immunohistochemical test in-
volving a multidrug resistance gene was carried out, in
which glutathione s-transferase scored as strongly posi-
tive. This finding may explain why the initial chemo-
therapy regimen was less efficacious than expected.
Based on this finding, a regimen of oxaliplatin, capecitabine,
and docetaxel was prescribed as a salvage treatment. To
our surprise, the liver metastatic foci responded well to this
chemotherapy regimen and there was a 10-month remis-
sion, despite the fact that this patient experienced temporal
myelosuppression, which was offset by colony-stimulating
factor.
During the whole period of treatment, serum tumor
markers might be one of the most important prognostic
factors that can reflect the efficacy of chemotherapy and
tumor recurrence. Consistent with other enteric-type
adenocarcinomas, urachal adenocarcinoma might express
detectable serum levels of CEA, CA125, and CA19-9 [32].
In our case, with the development of disease, these
markers, including CA724, CA125, CA19-9, and CEA,
were elevated in a linear pattern (Figure 5). Their levels
were increased in parallel with peritoneal carcinomatosis
and in parallel with a reduction in response to personal
chemotherapy. Among all of the tumor markers, the mostTable 4 Laboratory findings related to tumor markers at diffe
Tumor
markers
Index change in f
30 April 2007 8 August 2008 3 Decembe
CA19-9 88.38 kU/l 43.80 kU/l 158.30 k
CA724 15.24 kU/l 73.42 kU/l 2352.0 k
CA125 60.00 kU/l 19.11 kU/l 309.60 k
CA15-3 4.32 kU/l 5.91 kU/l 10.83 kU
CEA 9.49 ng/ml 4.08 ng/ml 43.62 μg
AFP 2.00 ng/ml 2.55 ng/ml 2.03 μg/significant elevation was achieved in CA724 level prior to
local recurrence and ovary metastasis (Table 4).
In conclusion, urachal carcinoma is not only a rare form
of tumor, but also a difficult-to-treat disease. We support
standard and radical resection to achieve a negative mar-
gin. However, even an enlarged or consecutive operation
is encouraged when recurrence or peritoneal carcinoma-
tosis occurs with a laparotomy. It is difficult to make an
exact diagnosis preoperatively and a systematic review of
all of the data is always essential in making a correct diag-
nosis based on the Mayo criteria. A standard chemothera-
peutic strategy still needs to be explored in future studies,
but personalized treatment can be given to those
patients who experience a poor response to initial
therapy. Moreover, an immunohistochemical test for
multidrug resistance gene and serum tumor markers
may supply key information in the choice of reasonable
chemotherapeutics.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for review
by the editor-in-chief of this journal.rent follow-up dates
ollow-up date Normal
ranger 2008 3 June 2009 20 December2009
U/l 57.15 kU/l 23.44 kU/l <37.00
U/l 1237.0 kU/l 47.50 kU/l <6.00
U/l 79.20 kU/l 10.00 kU/l <35.00
/l 11.56 kU/l 10.83 kU/l <30.00
/ml 13.87 μg/ml 3.06 μg/ml <5.00
ml 3.39 μg/ml 7.66 μg/ml <20.00
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